Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2018

Open Access 01-12-2018 | Research article

In-hospital major arrhythmias, arrhythmic death and resuscitation after successful primary percutaneous intervention for acute transmural infarction: a retrospective single-centre cohort study

Authors: Marco Albanese, Korhan Alpaslan, Taoufik Ouarrak, Peter Merguet, Steffen Schneider, Wolfgang Schöls

Published in: BMC Cardiovascular Disorders | Issue 1/2018

Login to get access

Abstract

Background

Transmural acute myocardial infarction (AMI) is associated with a high risk for ventricular arrhythmia before, during and after treatment. Consequently, it is recommended that patients diagnosed with transmural AMI be monitored in a cardiac care unit (CCU) so life-threatening arrhythmias can be treated promptly. We examined the incidence and timing of in-hospital malignant ventricular arrhythmias, sudden cardiac or arrhythmic death (SCD/AD) and resuscitation requirements in patients with transmural AMI recovering from percutaneous coronary intervention (PCI) undertaken within 12 h of symptom onset and without antecedent thrombolysis.

Methods

This was a retrospective cohort study using the Duisburg Heart Center (Germany) cardiac patient registry. In total, 975 patients met the inclusion criteria. The composite endpoint was post-PCI ventricular fibrillation or tachycardia, SCD/AD or requirement for resuscitation. We compared the demographic and clinical characteristics of patients who met the composite endpoint with those who did not, recorded the timing of endpoint episodes, and used multivariable logistic regression analysis to identify factors associated with the endpoint criteria.

Results

There was no significant difference in the length of CCU or hospital stay between the groups. In-hospital mortality was 6.5%, and the composite endpoint was met in 7.4% of cases. Malignant ventricular tachyarrhythmia occurred in 2.8% of the patients, and SCD/AD occurred in 0.3% of the cases. There was a biphasic temporal distribution of endpoint events; specifically, 76.7% occurred < 96 h after symptom onset, and 12.6% occurred 240–360 h after symptom onset. Multivariable regression analysis identified positive associations between an endpoint episode and the following: age (odds ratio [OR] 1.03, 95% confidence interval [CI] 1.01–1.05] per year); left ventricular ejection fraction (LVEF) < 30% (OR 3.66, 95% CI 1.91–6.99); peak serum creatine phosphokinase concentration (OR 1.01, 95% CI 1.00–1.02 per 100 U/dl); leucocytosis (OR 1.86, 95% CI 1.04–3.32), and coronary thrombus (OR 1.85, 95% CI 1.04–3.27).

Conclusions

Most post-PCI malignant ventricular arrhythmias, SCD/AD and resuscitation episodes occurred within 96 h of transmural AMI (76.7%). A substantial minority (12.6%) of these events arose 240–360 h after symptom onset. Further study is needed to establish the influence of age, LVEF < 30%, peak serum creatine phosphokinase concentration, leucocytosis and coronary thrombus on post-PCI outcomes after transmural AMI.
Literature
1.
go back to reference Henkel DM, Witt BJ, Gersh BJ, Jacobsen SJ, Weston SA, Meverden RA, et al. Ventricular arrhythmias after acute myocardial infarction: a 20-year community study. Am Heart J. 2006;151:806–12.CrossRefPubMed Henkel DM, Witt BJ, Gersh BJ, Jacobsen SJ, Weston SA, Meverden RA, et al. Ventricular arrhythmias after acute myocardial infarction: a 20-year community study. Am Heart J. 2006;151:806–12.CrossRefPubMed
2.
go back to reference Hasin Y, Danchin N, Filippatos GS, Heras M, Janssens U, Leor J, et al. Recommendations for the structure, organization, and operation of intensive cardiac care units. Eur Heart J. 2005;26:1676–82.CrossRefPubMed Hasin Y, Danchin N, Filippatos GS, Heras M, Janssens U, Leor J, et al. Recommendations for the structure, organization, and operation of intensive cardiac care units. Eur Heart J. 2005;26:1676–82.CrossRefPubMed
3.
go back to reference Kaul P, Newby LK, Fu Y, Mark DB, Califf RM, Topol EJ, et al. International differences in evolution of early discharge after acute myocardial infarction. Lancet. 2004;363:511–7.CrossRefPubMed Kaul P, Newby LK, Fu Y, Mark DB, Califf RM, Topol EJ, et al. International differences in evolution of early discharge after acute myocardial infarction. Lancet. 2004;363:511–7.CrossRefPubMed
4.
go back to reference Kozieradzka A, Kaminski KA, Maciorkowska D, Olszewska M, Dobrzycki S, Nowak K, et al. GRACE, TIMI, Zwolle and CADILLAC risk scores--do they predict 5-year outcomes after ST-elevation myocardial infarction treated invasively? Int J Cardiol. 2011;148:70–5.CrossRefPubMed Kozieradzka A, Kaminski KA, Maciorkowska D, Olszewska M, Dobrzycki S, Nowak K, et al. GRACE, TIMI, Zwolle and CADILLAC risk scores--do they predict 5-year outcomes after ST-elevation myocardial infarction treated invasively? Int J Cardiol. 2011;148:70–5.CrossRefPubMed
5.
go back to reference TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985;312:932–6.CrossRef TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985;312:932–6.CrossRef
6.
go back to reference Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20.CrossRefPubMed Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20.CrossRefPubMed
7.
go back to reference Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Aschermann M, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. Eur Heart J. 2003;24:94–104.CrossRefPubMed Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Aschermann M, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. Eur Heart J. 2003;24:94–104.CrossRefPubMed
8.
go back to reference Busk M, Maeng M, Rasmussen K, Kelbaek H, Thayssen P, Abildgaard U, et al. The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. Eur Heart J. 2008;29:1259–66.CrossRefPubMed Busk M, Maeng M, Rasmussen K, Kelbaek H, Thayssen P, Abildgaard U, et al. The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. Eur Heart J. 2008;29:1259–66.CrossRefPubMed
9.
go back to reference Giglioli C, Margheri M, Valente S, Comeglio M, Lazzeri C, Romano SM, et al. The incidence and timing of major arrhythmias following successful primary angioplasty for acute myocardial infarction. Ital Heart J. 2005;6:28–34.PubMed Giglioli C, Margheri M, Valente S, Comeglio M, Lazzeri C, Romano SM, et al. The incidence and timing of major arrhythmias following successful primary angioplasty for acute myocardial infarction. Ital Heart J. 2005;6:28–34.PubMed
10.
go back to reference Giglioli C, Margheri M, Valente S, Comeglio M, Lazzeri C, Chechi T, et al. Timing, setting and incidence of cardiovascular complications in patients with acute myocardial infarction submitted to primary percutaneous coronary intervention. Can J Cardiol. 2006;22:1047–52.CrossRefPubMedPubMedCentral Giglioli C, Margheri M, Valente S, Comeglio M, Lazzeri C, Chechi T, et al. Timing, setting and incidence of cardiovascular complications in patients with acute myocardial infarction submitted to primary percutaneous coronary intervention. Can J Cardiol. 2006;22:1047–52.CrossRefPubMedPubMedCentral
11.
go back to reference Cricri P, Trachsel L, Muller P, Wackerlin A, Reinhart W, Bonetti P. Incidence and time frame of life-threatening arrhythmias in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Swiss Med Wkly. 2012;8:13604. Cricri P, Trachsel L, Muller P, Wackerlin A, Reinhart W, Bonetti P. Incidence and time frame of life-threatening arrhythmias in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Swiss Med Wkly. 2012;8:13604.
12.
go back to reference Ohlow M, Geller J, Richter S, Farah A, Muller S, Fuhrmann J, et al. Incidence and predictors of ventricular arrhythmias after ST-segment elevation myocardial infarction. Am J Emerg Med. 2012;30:580–6.CrossRefPubMed Ohlow M, Geller J, Richter S, Farah A, Muller S, Fuhrmann J, et al. Incidence and predictors of ventricular arrhythmias after ST-segment elevation myocardial infarction. Am J Emerg Med. 2012;30:580–6.CrossRefPubMed
13.
go back to reference Mehta R, Starr A, Lopes R, Hochman J, Widimsky P, Pieper K, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA. 2009;301:1779–89.CrossRefPubMed Mehta R, Starr A, Lopes R, Hochman J, Widimsky P, Pieper K, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA. 2009;301:1779–89.CrossRefPubMed
14.
go back to reference Mehta R, Yu J, Piccini J, Tcheng J, Farkouh M, Reiffel J, et al. Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI trial). Am J Cardiol. 2012;109:805–12.CrossRefPubMed Mehta R, Yu J, Piccini J, Tcheng J, Farkouh M, Reiffel J, et al. Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI trial). Am J Cardiol. 2012;109:805–12.CrossRefPubMed
15.
go back to reference Newby K, Thompson T, Stebbins A, Topol E, Califf R, Natale A. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circ. 1998;98:2567–73.CrossRef Newby K, Thompson T, Stebbins A, Topol E, Califf R, Natale A. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circ. 1998;98:2567–73.CrossRef
16.
go back to reference Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I investigators. Circ. 1995;91:1659–68.CrossRef Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I investigators. Circ. 1995;91:1659–68.CrossRef
17.
go back to reference Rahimi K, Watzlawek S, Thiele H, Secknus MA, Hayerizadeh BF, Niebauer J, et al. Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST segment elevation myocardial infarction in patients with early invasive treatment. Eur Heart J. 2006;27:1706–11.CrossRefPubMed Rahimi K, Watzlawek S, Thiele H, Secknus MA, Hayerizadeh BF, Niebauer J, et al. Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST segment elevation myocardial infarction in patients with early invasive treatment. Eur Heart J. 2006;27:1706–11.CrossRefPubMed
18.
go back to reference Josephson R, Papa L, Brooks M, Morris M, Akiyama T, Greene H. Effect of age on postmyocardial infarction ventricular arrhythmias (Holter registry data from CAST I and CAST II). Cardiovascular arrhythmia suppression trials. Am J Cardiol. 1995;76:710–3.CrossRefPubMed Josephson R, Papa L, Brooks M, Morris M, Akiyama T, Greene H. Effect of age on postmyocardial infarction ventricular arrhythmias (Holter registry data from CAST I and CAST II). Cardiovascular arrhythmia suppression trials. Am J Cardiol. 1995;76:710–3.CrossRefPubMed
19.
go back to reference Ruiz-Bailen M, Aguayo de Hoyos E, Ruiz-Navarro S, Issa-Khozouz Z, Reina-Toral A, Diaz-Castellanos MA, et al. Ventricular fibrillation in acute myocardial infarction in Spanish patients: results of the ARIAM database. Crit Care Med. 2003;31:2144–51.CrossRefPubMed Ruiz-Bailen M, Aguayo de Hoyos E, Ruiz-Navarro S, Issa-Khozouz Z, Reina-Toral A, Diaz-Castellanos MA, et al. Ventricular fibrillation in acute myocardial infarction in Spanish patients: results of the ARIAM database. Crit Care Med. 2003;31:2144–51.CrossRefPubMed
20.
go back to reference Mont L, Cinca J, Blanch P, Blanco J, Figueras J, Brotons C, et al. Predisposing factors and prognostic value of sustained monomorphic ventricular tachycardia in the early phase of acute myocardial infarction. J Am Coll Cardiol. 1996;28:1670–6.CrossRefPubMed Mont L, Cinca J, Blanch P, Blanco J, Figueras J, Brotons C, et al. Predisposing factors and prognostic value of sustained monomorphic ventricular tachycardia in the early phase of acute myocardial infarction. J Am Coll Cardiol. 1996;28:1670–6.CrossRefPubMed
21.
go back to reference Su Y, Cai X, Geng H, Sheng H, Fan M, Pan M. In-hospital clinical outcomes of elderly patients (>/=60 years) undergoing primary percutaneous coronary intervention. Int J Clin Exp Med. 2015;8:11244–51.PubMedPubMedCentral Su Y, Cai X, Geng H, Sheng H, Fan M, Pan M. In-hospital clinical outcomes of elderly patients (>/=60 years) undergoing primary percutaneous coronary intervention. Int J Clin Exp Med. 2015;8:11244–51.PubMedPubMedCentral
22.
go back to reference Barron H, Cannon C, Murphy S, Braunwald E, Gibson C. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circ. 2000;102:2329–34.CrossRef Barron H, Cannon C, Murphy S, Braunwald E, Gibson C. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circ. 2000;102:2329–34.CrossRef
23.
go back to reference Huber K, Ducrocq G, Hamm CW, Van ‘t Hof A, Lapostolle F, Coste P, et al. Early clinical outcomes as a function of use of newer oral P2Y12 inhibitors versus clopidogrel in the EUROMAX trial. Open Heart. 2017;4:e000677.CrossRefPubMedPubMedCentral Huber K, Ducrocq G, Hamm CW, Van ‘t Hof A, Lapostolle F, Coste P, et al. Early clinical outcomes as a function of use of newer oral P2Y12 inhibitors versus clopidogrel in the EUROMAX trial. Open Heart. 2017;4:e000677.CrossRefPubMedPubMedCentral
24.
go back to reference Motovska Z, Hlinomaz O, Kala P, Hromadka M, Knot J, Varvarovsky I, et al. 1-year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J Am Coll Cardiol. 2018;71:371–81.CrossRefPubMed Motovska Z, Hlinomaz O, Kala P, Hromadka M, Knot J, Varvarovsky I, et al. 1-year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J Am Coll Cardiol. 2018;71:371–81.CrossRefPubMed
25.
go back to reference Wang L, Wang H, Dong P, Li Z, Wang Y, Duan N, et al. Long-term outcomes of drug-eluting versus bare-metal stent for ST-elevation myocardial infarction. Arq Bras Cardiol. 2014;102:529–38.PubMedPubMedCentral Wang L, Wang H, Dong P, Li Z, Wang Y, Duan N, et al. Long-term outcomes of drug-eluting versus bare-metal stent for ST-elevation myocardial infarction. Arq Bras Cardiol. 2014;102:529–38.PubMedPubMedCentral
26.
go back to reference Stella SF, Gehling Bertoldi E, Polanczyk CA. Contemporary context of drug-eluting stents in Brazil: a cost utility study. Med Decis Mak. 2016;36:1034–42.CrossRef Stella SF, Gehling Bertoldi E, Polanczyk CA. Contemporary context of drug-eluting stents in Brazil: a cost utility study. Med Decis Mak. 2016;36:1034–42.CrossRef
27.
go back to reference Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Yamaji K, et al. Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 years) follow-up of the coronary revascularization demonstrating outcome study-Kyoto registry Cohort-2. Circ Cardiovasc Interv. 2014;7:168–79.CrossRefPubMed Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Yamaji K, et al. Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 years) follow-up of the coronary revascularization demonstrating outcome study-Kyoto registry Cohort-2. Circ Cardiovasc Interv. 2014;7:168–79.CrossRefPubMed
28.
go back to reference Lee VW, Cheng FW, Choi AY, Fong ST, Yu CM, Yan BP. Clinical, humanistic, and economic outcomes between drug-eluting stent (DES) and bare metal stent (BMS): 18-month follow-up study. J Med Econ. 2017;20:239–45.CrossRefPubMed Lee VW, Cheng FW, Choi AY, Fong ST, Yu CM, Yan BP. Clinical, humanistic, and economic outcomes between drug-eluting stent (DES) and bare metal stent (BMS): 18-month follow-up study. J Med Econ. 2017;20:239–45.CrossRefPubMed
29.
go back to reference Iqbal MB, Nadra IJ, Ding L, Fung A, Aymong E, Chan AW, et al. Long-term outcomes following drug-eluting stents versus bare metal stents for primary percutaneous coronary intervention: a real-world analysis of 11,181 patients from the British Columbia cardiac registry. Catheter Cardiovasc Interv. 2016;88:24–35.CrossRefPubMed Iqbal MB, Nadra IJ, Ding L, Fung A, Aymong E, Chan AW, et al. Long-term outcomes following drug-eluting stents versus bare metal stents for primary percutaneous coronary intervention: a real-world analysis of 11,181 patients from the British Columbia cardiac registry. Catheter Cardiovasc Interv. 2016;88:24–35.CrossRefPubMed
30.
go back to reference Bonaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygard O, et al. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016;375:1242–52.CrossRefPubMed Bonaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygard O, et al. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016;375:1242–52.CrossRefPubMed
31.
go back to reference Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451.CrossRefPubMedPubMedCentral Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451.CrossRefPubMedPubMedCentral
Metadata
Title
In-hospital major arrhythmias, arrhythmic death and resuscitation after successful primary percutaneous intervention for acute transmural infarction: a retrospective single-centre cohort study
Authors
Marco Albanese
Korhan Alpaslan
Taoufik Ouarrak
Peter Merguet
Steffen Schneider
Wolfgang Schöls
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2018
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-018-0851-z

Other articles of this Issue 1/2018

BMC Cardiovascular Disorders 1/2018 Go to the issue